Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Tokyo VD who wrote (5192)	8/11/1998 1:33:00 PM
From: Dauntless	Read Replies (1) \| Respond to of 7041

Tokyo - what multitude are you speaking of? The following paragraph is from the FDA web site (link provided below). >>>For example, of 100 drugs for which investigational new drug applications are submitted to FDA, about 70 will successfully complete phase 1 trials and go on to phase 2; about 33 of the original 100 will complete phase 2 and go to phase 3; and 25 to 30 of the original 100 will clear phase 3 (and, on average, about 20 of the original 100 will ultimately be approved for marketing).<<< It looks to me like only 20 of every 100 drugs that starts the approval process (i.e. - file an IND application) winds up getting approved - the 80 that fall out must be what you were referring to by "multitude". However, of the 25-30 that complete phase 3, 20 get approved. That's a 67% - 80% approval percentage!!! That's because the trial designs & results are reviewed with the FDA all the way through the process. And that's why I wrote ... "Vasomax's statistics are more than adequate to satisfy the FDA - why would they file if they weren't?" The FDA web site is titled "Testing Drugs in People" and can be read at: fda.gov The stats I posted above are on a link part way through the page. I think accurate information is the best way to assess these investment opportunities, don't you?